Ironwood Pharmaceuticals (IRWD) Income from Continuing Operations (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Income from Continuing Operations across 17 years of filings, most recently posting 40772000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 40772000.0, up 209.1% year-over-year; the trailing twelve-month figure through Mar 2026 was 18156000.0 (up 86.17% YoY), and the FY2025 annual result was 96337000.0, up 1.86% from the prior year.
• Income from Continuing Operations came in at 40772000.0 for Q1 2026 at Ironwood Pharmaceuticals, up from 122630000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 50317000.0 in Q3 2022 to a low of 1089522000.0 in Q2 2023.
• The 5-year median for Income from Continuing Operations is 13932000.0 (2023), against an average of 72748941.18.
• Across the five-year window, Income from Continuing Operations tumbled 3038.3% in 2023 and surged 2966.75% in 2025, its largest moves.
• Ironwood Pharmaceuticals' Income from Continuing Operations stood at 48867000.0 in 2022, then slumped by 567.14% to 228277000.0 in 2023, then soared by 57.61% to 96763000.0 in 2024, then retreated by 26.73% to 122630000.0 in 2025, then soared by 133.25% to 40772000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 40772000.0 (Q1 2026), 122630000.0 (Q4 2025), and 40080000.0 (Q3 2025), per Business Quant data.